SK Biopharmaceuticals agreed to acquire Biohaven’s Phase II/III epilepsy candidate opakalim (BHV-7000, Kv7.2/7.3 activator) in a deal valued at up to $795 million. The payment includes $400 million at signing/closing (with $350 million at closing and $50 million due in 2027), with the transaction giving SK a commercial partner platform already established in epilepsy markets through XCOPRI. Both companies framed the structure around accelerating commercialization by leveraging SK’s neurology field force, payer/formulary access, and patient support infrastructure. The deal also reflects ongoing investor and pharma emphasis on adding differentiated therapies to epilepsy franchises with defined payer and clinic coverage. Completion is subject to Hart-Scott-Rodino clearance and customary conditions. Industry watchers will now track development and integration planning as opakalim moves toward potential late-stage milestones under SK’s commercial umbrella.